<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes	(indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier			N/A
name, catalogue number and RRID, if available.			

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.	Methods /Cell culture and cell transfection	
Provide accession number in repository OR		
supplier name, catalog number, clone number,		
OR RRID		
Primary cultures: Provide species, strain, sex of		N/A
origin, genetic modification status.		

Experimental animals	Yes	(indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,			N/A
genetic modification status. Provide accession			
number in repository OR supplier name, catalog			
number, clone number, OR RRID			
Animal observed in or captured from the			N/A
field: Provide species, sex and age where			
possible			
Model organisms: Provide Accession number			N/A
in repository (where relevant) OR RRID			

Plants and microbes	Yes	(indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)			N/A
Microbes: provide species and strain, unique accession number if available, and source			N/A

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Methods / Patients and samples	
Provide statement confirming informed consent obtained from study participants.	Methods / Patients and samples	
Report on age and sex for all study participants.		N/A

<u>Design</u>

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration		N/A
number OR cite DOI in manuscript.		
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-	Methods /Cell culture and cell transfection	
by-step protocols are available.	Methods / Cell proliferation assays	
	Methods / Cell cycle analysis	
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been	, , , , , , , , , , , , , , , , , , , ,	
done, or if they were not carried out.		
Sample size determination		N/A
Randomisation		N/A
Blinding		N/A
Inclusion/exclusion criteria		N/A
		·
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was	Methods /Cell culture and cell transfection	
replicated in laboratory	Methods / RNA extraction and qRT-PCR	
	Methods / Cell proliferation assays	
	Methods / Cell cycle analysis	
Define whether data describe technical or biological		N/A
replicates		
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of	Methods / Patients and samples	
authority granting ethics approval (IRB or equivalent		
committee(s), provide reference number for		
approval.		
Studies involving experimental animals: State details		N/A
of authority granting ethics approval (IRB or		
equivalent committee(s), provide reference number		
for approval.		
Studies involving specimen and field samples: State if		N/A
relevant permits obtained, provide details of		
authority approving study; if none were required,		
explain why.		
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
Dual Ose Research of Concern (Done)	163 (maicate where provided, section, paragraph)	II/ d

Analysis

Attrition	Yes	(indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is			N/A
excluded, and whether the criteria for exclusion were			
determined and specified in advance.			

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of	Methods / Statistical analysis	
tests.		

Data Availability	Yes	(indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,			N/A
including protocols for access or restriction on			
access.			
If data are publicly available, provide accession			N/A
number in repository or DOI or URL.			
If publicly available data are reused, provide			N/A
accession number in repository or DOI or URL, where			
possible.			

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.		N/A
If code is publicly available, provide accession		N/A
number in repository, or DOI or URL.		

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

 $Article\ information: \underline{https://dx.doi.org/10.21037/atm-22-1956}$